Neurology Clinical Trials Market (By Phase: Phase I, Phase II, Phase III, Phase IV; By Study Design: Interventional, Observational, Expanded Access; By Indication: Epilepsy, Parkinson's Disease (PD), Huntington's Disease, Stroke, Traumatic Brain Injury (TBI), Amyotrophic Lateral Sclerosis (ALS), Muscle regeneration, Others) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook 20212030

Chapter 1.  Introduction

1.1.  Research Objective

1.2.  Scope of the Study

1.3.  Definition

Chapter 2.  Research Methodology

2.1.  Research Approach

2.2.  Data Sources

2.3.  Assumptions & Limitations

Chapter 3.  Executive Summary

3.1.  Market Snapshot

Chapter 4.  Market Variables and Scope

4.1.  Introduction

4.2.  Market Classification and Scope

4.3.  Industry Value Chain Analysis

4.3.1.    Raw Material Procurement Analysis

4.3.2.    Sales and Distribution Channel Analysis

4.3.3.    Downstream Buyer Analysis

Chapter 5.  Market Dynamics Analysis and Trends

5.1.  Market Dynamics

5.1.1.    Market Drivers

5.1.2.    Market Restraints

5.1.3.    Market Opportunities

5.2.  Porter’s Five Forces Analysis

5.2.1.    Bargaining power of suppliers

5.2.2.    Bargaining power of buyers

5.2.3.    Threat of substitute

5.2.4.    Threat of new entrants

5.2.5.    Degree of competition

Chapter 6.  Competitive Landscape

6.1.1.    Company Market Share/Positioning Analysis

6.1.2.    Key Strategies Adopted by Players

6.1.3.    Vendor Landscape

6.1.3.1.        List of Suppliers

6.1.3.2.        List of Buyers

Chapter 7.  Global Neurology Clinical Trials Market, By Phase

7.1.  Neurology Clinical Trials Market, by Phase, 2021-2030

7.1.1.    Phase I

7.1.1.1.        Market Revenue and Forecast (2017-2030)

7.1.2.    Phase II

7.1.2.1.        Market Revenue and Forecast (2017-2030)

7.1.3.    Phase III

7.1.3.1.        Market Revenue and Forecast (2017-2030)

7.1.4.    Phase IV

7.1.4.1.        Market Revenue and Forecast (2017-2030)

Chapter 8.  Global Neurology Clinical Trials Market, By Study Design

8.1.  Neurology Clinical Trials Market, by Study Design, 2021-2030

8.1.1.    Interventional

8.1.1.1.        Market Revenue and Forecast (2017-2030)

8.1.2.    Observational

8.1.2.1.        Market Revenue and Forecast (2017-2030)

8.1.3.    Expanded Access

8.1.3.1.        Market Revenue and Forecast (2017-2030)

Chapter 9.  Global Neurology Clinical Trials Market, By Indication

9.1.  Neurology Clinical Trials Market, by Indication, 2021-2030

9.1.1.    Epilepsy

9.1.1.1.        Market Revenue and Forecast (2017-2030)

9.1.2.    Parkinson's Disease (PD)

9.1.2.1.        Market Revenue and Forecast (2017-2030)

9.1.3.    Huntington's Disease

9.1.3.1.        Market Revenue and Forecast (2017-2030)

9.1.4.    Stroke

9.1.4.1.        Market Revenue and Forecast (2017-2030)

9.1.5.    Traumatic Brain Injury (TBI)

9.1.5.1.        Market Revenue and Forecast (2017-2030)

9.1.6.    Amyotrophic Lateral Sclerosis (ALS)

9.1.6.1.        Market Revenue and Forecast (2017-2030)

9.1.7.    Muscle regeneration

9.1.7.1.        Market Revenue and Forecast (2017-2030)

9.1.8.    Others

9.1.8.1.        Market Revenue and Forecast (2017-2030)

Chapter 10.      Global Neurology Clinical Trials Market, Regional Estimates and Trend Forecast

10.1.        North America

10.1.1.  Market Revenue and Forecast, by Phase (2017-2030)

10.1.2.  Market Revenue and Forecast, by Study Design (2017-2030)

10.1.3.  Market Revenue and Forecast, by Indication (2017-2030)

10.1.4.  U.S.

10.1.4.1.      Market Revenue and Forecast, by Phase (2017-2030)

10.1.4.2.      Market Revenue and Forecast, by Study Design (2017-2030)

10.1.4.3.      Market Revenue and Forecast, by Indication (2017-2030)

10.1.5.  Rest of North America

10.1.5.1.      Market Revenue and Forecast, by Phase (2017-2030)

10.1.5.2.      Market Revenue and Forecast, by Study Design (2017-2030)

10.1.5.3.      Market Revenue and Forecast, by Indication (2017-2030)

10.2.        Europe

10.2.1.  Market Revenue and Forecast, by Phase (2017-2030)

10.2.2.  Market Revenue and Forecast, by Study Design (2017-2030)

10.2.3.  Market Revenue and Forecast, by Indication (2017-2030)

10.2.4.  UK

10.2.4.1.      Market Revenue and Forecast, by Phase (2017-2030)

10.2.4.2.      Market Revenue and Forecast, by Study Design (2017-2030)

10.2.4.3.      Market Revenue and Forecast, by Indication (2017-2030)

10.2.5.  Germany

10.2.5.1.      Market Revenue and Forecast, by Phase (2017-2030)

10.2.5.2.      Market Revenue and Forecast, by Study Design (2017-2030)

10.2.5.3.      Market Revenue and Forecast, by Indication (2017-2030)

10.2.6.  France

10.2.6.1.      Market Revenue and Forecast, by Phase (2017-2030)

10.2.6.2.      Market Revenue and Forecast, by Study Design (2017-2030)

10.2.6.3.      Market Revenue and Forecast, by Indication (2017-2030)

10.2.7.  Rest of Europe

10.2.7.1.      Market Revenue and Forecast, by Phase (2017-2030)

10.2.7.2.      Market Revenue and Forecast, by Study Design (2017-2030)

10.2.7.3.      Market Revenue and Forecast, by Indication (2017-2030)

10.3.        APAC

10.3.1.  Market Revenue and Forecast, by Phase (2017-2030)

10.3.2.  Market Revenue and Forecast, by Study Design (2017-2030)

10.3.3.  Market Revenue and Forecast, by Indication (2017-2030)

10.3.4.  India

10.3.4.1.      Market Revenue and Forecast, by Phase (2017-2030)

10.3.4.2.      Market Revenue and Forecast, by Study Design (2017-2030)

10.3.4.3.      Market Revenue and Forecast, by Indication (2017-2030)

10.3.5.  China

10.3.5.1.      Market Revenue and Forecast, by Phase (2017-2030)

10.3.5.2.      Market Revenue and Forecast, by Study Design (2017-2030)

10.3.5.3.      Market Revenue and Forecast, by Indication (2017-2030)

10.3.6.  Japan

10.3.6.1.      Market Revenue and Forecast, by Phase (2017-2030)

10.3.6.2.      Market Revenue and Forecast, by Study Design (2017-2030)

10.3.6.3.      Market Revenue and Forecast, by Indication (2017-2030)

10.3.7.  Rest of APAC

10.3.7.1.      Market Revenue and Forecast, by Phase (2017-2030)

10.3.7.2.      Market Revenue and Forecast, by Study Design (2017-2030)

10.3.7.3.      Market Revenue and Forecast, by Indication (2017-2030)

10.4.        MEA

10.4.1.  Market Revenue and Forecast, by Phase (2017-2030)

10.4.2.  Market Revenue and Forecast, by Study Design (2017-2030)

10.4.3.  Market Revenue and Forecast, by Indication (2017-2030)

10.4.4.  GCC

10.4.4.1.      Market Revenue and Forecast, by Phase (2017-2030)

10.4.4.2.      Market Revenue and Forecast, by Study Design (2017-2030)

10.4.4.3.      Market Revenue and Forecast, by Indication (2017-2030)

10.4.5.  North Africa

10.4.5.1.      Market Revenue and Forecast, by Phase (2017-2030)

10.4.5.2.      Market Revenue and Forecast, by Study Design (2017-2030)

10.4.5.3.      Market Revenue and Forecast, by Indication (2017-2030)

10.4.6.  South Africa

10.4.6.1.      Market Revenue and Forecast, by Phase (2017-2030)

10.4.6.2.      Market Revenue and Forecast, by Study Design (2017-2030)

10.4.6.3.      Market Revenue and Forecast, by Indication (2017-2030)

10.4.7.  Rest of MEA

10.4.7.1.      Market Revenue and Forecast, by Phase (2017-2030)

10.4.7.2.      Market Revenue and Forecast, by Study Design (2017-2030)

10.4.7.3.      Market Revenue and Forecast, by Indication (2017-2030)

10.5.        Latin America

10.5.1.  Market Revenue and Forecast, by Phase (2017-2030)

10.5.2.  Market Revenue and Forecast, by Study Design (2017-2030)

10.5.3.  Market Revenue and Forecast, by Indication (2017-2030)

10.5.4.  Brazil

10.5.4.1.      Market Revenue and Forecast, by Phase (2017-2030)

10.5.4.2.      Market Revenue and Forecast, by Study Design (2017-2030)

10.5.4.3.      Market Revenue and Forecast, by Indication (2017-2030)

10.5.5.  Rest of LATAM

10.5.5.1.      Market Revenue and Forecast, by Phase (2017-2030)

10.5.5.2.      Market Revenue and Forecast, by Study Design (2017-2030)

10.5.5.3.      Market Revenue and Forecast, by Indication (2017-2030)

Chapter 11.  Company Profiles

11.1.              Novartis

11.1.1.  Company Overview

11.1.2.  Product Offerings

11.1.3.  Financial Performance

11.1.4.  Recent Initiatives

11.2.              Covance

11.2.1.  Company Overview

11.2.2.  Product Offerings

11.2.3.  Financial Performance

11.2.4.  Recent Initiatives

11.3.              Medpace

11.3.1.  Company Overview

11.3.2.  Product Offerings

11.3.3.  Financial Performance

11.3.4.  Recent Initiatives

11.4.              Charles River Laboratories

11.4.1.  Company Overview

11.4.2.  Product Offerings

11.4.3.  Financial Performance

11.4.4.  Recent Initiatives

11.5.              Syneous Health

11.5.1.  Company Overview

11.5.2.  Product Offerings

11.5.3.  Financial Performance

11.5.4.  Recent Initiatives

11.6.              Icon Plc

11.6.1.  Company Overview

11.6.2.  Product Offerings

11.6.3.  Financial Performance

11.6.4.  Recent Initiatives

11.7.              GlaxoSmithKline

11.7.1.  Company Overview

11.7.2.  Product Offerings

11.7.3.  Financial Performance

11.7.4.  Recent Initiatives

11.8.              Aurora healthcare

11.8.1.  Company Overview

11.8.2.  Product Offerings

11.8.3.  Financial Performance

11.8.4.  Recent Initiatives

11.9.              Biogen

11.9.1.  Company Overview

11.9.2.  Product Offerings

11.9.3.  Financial Performance

11.9.4.  Recent Initiatives

11.10.           IQVIA

11.10.1.               Company Overview

11.10.2.               Product Offerings

11.10.3.               Financial Performance

11.10.4.               Recent Initiatives

Chapter 12.  Research Methodology

12.1.              Primary Research

12.2.              Secondary Research

12.3.              Assumptions

Chapter 13.  Appendix

13.1.              About Us

13.2.              Glossary of Terms

Report Details

  • Report Code:38683
  • Category:Healthcare
  • No. of Pages:150+
  • Format:PDF/PPT/Excel
  • Published:October 2021
  • Historical Year:2021-2022
  • Base Year:2023
  • Estimated Year:2024-2033

Proceed To Buy

USD 4500
USD 3800
USD 1900
USD 1200

Customization Offered

  • check-imgCross-segment Market Size and Analysis for Mentioned Segments
  • check-imgAdditional Company Profiles (Upto 5 With No Cost)
  • check-img Additional Countries (Apart From Mentioned Countries)
  • check-img Country/Region-specific Report
  • check-img Go To Market Strategy
  • check-imgRegion Specific Market Dynamics
  • check-imgRegion Level Market Share
  • check-img Import Export Analysis
  • check-imgProduction Analysis
  • check-imgOthers